Clinical Trial

Haematococcus Pluvialis Astaxanthin for Brain Aging

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
We recruit community-dwelling older adults aged 50 and above for a 6-month intervention. Participants are divided into three groups: Placebo Group, Low-Dose Group ( 6 mg/d Haematococcus pluvialis Astaxanthin), High-Dose Group (12 mg/d Haematococcus pluvialis Astaxanthin). Peripheral blood samples and Other tests are collected at baseline, 3 months, and 6 months to measure mitochondrial function and oxidative stress levels. Assessments include: 1.Cognitive \& Neurophysiological Assessment: Using the MoCA (Montreal Cognitive Assessmentscale) and ERP (specifically P300) monitoring. 2.Brain Imaging: MRI (Magnetic resonance imaging) is used to analyze changes in brain function. 3.Metabolomics: A series of laboratory techniques are used to analyze routine metabolic indices, plasma astaxanthin, mitochondrial function, oxidative stress markers, and cognition-related neurobiomarkers.
Trial Details
NCT Number NCT07379437
Lead Sponsor Capital Medical University
Conditions Brain Aging
Enrollment 120 participants
Start Date 2026-05-01
Primary Completion 2026-12-01 (estimated)
Study Completion 2027-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-30